Laboratory-Developed Test Startups After the FDA Rule Vacatur: A Physician Investor Due Diligence Guide

Bottom line. The federal court's March 31, 2025 vacatur of FDA's laboratory-developed-test rule removed the rule's staged phaseout timetable; FDA then restored the prior wording of 21 CFR 809.3(a) in September 2025.^[1][2] It did not make diagnostic-company risk disappear. Physician investors should now underwrite an LDT startup as an integrated laboratory business: define exactly what is made and where it is used, verify CLIA high-complexity performance, separate analytical validity from clinical validity and utility, test state-specific approvals, trace coverage and coding to collected cash, and model the operational constraints of a centralized laboratory. The investable moat is not the label "LDT." It is a reproducible evidence-and-delivery system that produces a trustworthy result, changes care, earns payment, and scales without quietly changing regulatory category.

Key takeaways

• The 2024 FDA phaseout schedule is not a current operating milestone. Forecasts and compliance reserves built around that vacated rule should be replaced with a fact-specific regulatory map.^[1][2]
• CLIA and FDA answer different questions. CLIA governs laboratory quality; product configuration, manufacturing, distribution, claims, and intended use still determine whether other FDA device obligations may matter.^[3][4]
• An LDT or laboratory-modified test defaults to high complexity under CLIA, which changes personnel, inspection, quality-system, and validation expectations.^[5]
• Analytical validity, clinical validity, and clinical utility are separate assets. A precise assay can still be commercially weak if the result does not improve a decision in the intended population.
• New York can be a separate launch gate. A laboratory testing New York specimens generally needs CLEP approval for its LDT even when operating outside the state.^[8]
• Coverage is not created by a CLIA certificate, a CPT code, or a fee-schedule amount. MolDX and other contractor policies can require test-specific evidence and identifiers.^[9][10]
• The centralized-lab architecture can be both moat and bottleneck. Specimen acquisition, accessioning, turnaround time, staffing, capacity, downtime, recollection, and report delivery belong in the valuation model.

What changed after the FDA rule vacatur

FDA's May 2024 final rule amended the definition of in vitro diagnostic products and paired that change with a multi-year phaseout of the agency's general enforcement-discretion approach for many IVDs offered as LDTs. A federal district court vacated the rule on March 31, 2025. FDA's current LDT page records that result, and the agency's September 19, 2025 final rule says the regulatory-text restoration was ministerial because the court had already set the rule aside.^[1][2] Therefore, a board should not treat the vacated stages as deadlines that automatically apply to its portfolio company.

The reset is not a blanket product classification

The practical question is not whether management calls the assay an LDT. It is who designs and manufactures each component, where the test is performed, whether the same laboratory uses it, what crosses organizational boundaries, who receives the report, and what clinical claims are made. CMS's LDT overview describes the traditional model as an IVD manufactured and used within a single laboratory with a single CLIA certificate, while distinguishing laboratory oversight from device oversight.^[4] A distributed reagent kit, instrument, collection device, consumer-facing workflow, licensed algorithm, or replicated multi-site assay may not share one answer. Diligence should document facts first and obtain a current legal and regulatory conclusion second.

CLIA remains the operating floor

CMS states that CLIA regulates laboratory testing on human specimens in the United States, except research, to support accurate, reliable, and timely results. Requirements rise with test complexity, and CLIA certification is necessary for laboratories that bill Medicare or Medicaid even though CLIA itself does not decide Medicare coverage or payment.^[3] CDC states that laboratory-developed or laboratory-modified tests default to high complexity and that nonwaived testing is subject to inspection, quality standards, proficiency testing, quality control, and personnel requirements.^[5] This is not a certificate-on-the-wall diligence item; it is the operating system of the company.

Map the business model before valuing the test

A diagnostic startup can combine several regulated and commercial layers under one brand. Build a component map that follows the specimen from ordering through collection, transport, accessioning, preparation, analysis, algorithmic interpretation, pathologist or laboratory-director review, reporting, storage, and billing. Then match each layer to its legal entity, site, CLIA certificate, state permit, vendor, software version, quality record, claim, and customer contract. The map should also show which changes can be made without altering the validated method or business perimeter.

Separate the four evidence layers

1. Analytical validity: does this production assay measure reliably?

For a test system developed in-house, CLIA performance specifications are not a generic literature exercise. CMS's interpretive guidance for section 493.1253 addresses accuracy, precision, analytical sensitivity and specificity, reportable range, reference intervals, and other performance characteristics before reporting patient results.^[6] Request the signed protocol and final report, raw runs, sample selection, acceptance criteria, failed studies, operator and instrument variation, interfering substances, limit studies, lot changes, reference methods, version identifiers, and approval by the laboratory director. Confirm that the dossier matches the assay, specimen type, instrument, software, cutoff, and report in production today.

2. Clinical validity: does the result predict the claimed condition?

Clinical validity connects a measurement to a disease, prognosis, treatment response, or other claimed state in the intended population. Review the reference standard, spectrum of disease, prevalence, enrollment, exclusions, sample provenance, blinding, missing data, threshold selection, confidence intervals, subgroup performance, external validation, and transportability to commercial patients. A model trained on curated biobank samples can underperform after real-world preanalytics, lower prevalence, demographic shift, comorbidity, or a new instrument. Do not let analytical precision stand in for clinical validity.

3. Clinical utility: does using the result improve a decision?

Clinical utility asks whether the test changes management in a way that matters. Define the target clinician, decision point, alternative pathway, actionability, timing, downstream procedures, patient access, and outcome. Evidence may include prospective utility studies, decision-impact studies, pragmatic evaluations, or credible linked evidence, depending on the claim and payer. Measure both beneficial and harmful downstream effects: avoided procedures, earlier appropriate treatment, false reassurance, incidental findings, repeat testing, delays, and inequitable access. Investors should distinguish management's inference from evidence actually observed.

4. Operational validity: can the system reproduce the promise every day?

Commercial performance includes the entire testing cycle. Track order completeness, specimen rejection, stability excursions, shipping delays, accession errors, batch failure, quality-control failure, reruns, recollections, contamination, no-calls, amended reports, turnaround percentiles, clinician questions, complaints, and corrective actions. CMS maintains approved proficiency-testing programs and current 2026 materials for regulated analytes.^[7] Where formal proficiency testing is unavailable, the laboratory should still show a documented alternative performance-assessment process and how discrepant findings trigger investigation and remediation.

State approval can define the real launch sequence

Federal analysis is only one layer. New York's Clinical Laboratory Evaluation Program states that a laboratory seeking to test New York specimens must obtain CLEP approval for an LDT even if the laboratory is outside New York.^[8] Request a state-by-state matrix covering laboratory permits, test approval, personnel, collection sites, telehealth ordering, consumer access, genetic-testing rules, result reporting, and renewal dates. Reconcile the matrix to the customer pipeline. A national demand forecast can be misleading if a major health system or employer population cannot legally enter the launch cohort on schedule.

Coverage, coding, and payment are three different gates

A valid test does not automatically become reimbursable. Start with a specific patient, indication, ordering clinician, payer, jurisdiction, site, code, documentation set, and date of service. CMS pays most clinical diagnostic laboratory tests under the Clinical Laboratory Fee Schedule, which is based largely on private-payor rates; CMS also reported a May 1 through July 31, 2026 data-reporting period and payment-reduction limits beginning in 2027.^[9] Those facts influence price pressure and reporting operations, but a fee amount still does not establish coverage for a new test.

MolDX turns the evidence stack into a coverage file

The 2026 MolDX molecular-diagnostic LCD applies test-specific identifiers and technical assessment to covered molecular tests, including non-FDA-cleared LDTs. It asks whether the service is reasonable and necessary and describes evidence of analytical validity, clinical validity, and clinical utility.^[10] For an affected market, request the registration, identifier, technical-assessment dossier, coverage decision, effective date, billing article, code crosswalk, documentation requirements, and claim edits. Then reconcile forecasted lives to actual contractor jurisdictions and covered indications.

Rebuild revenue from adjudicated claims

Obtain claim-level data from order to cash. Calculate clean-claim rate, denial categories, appeal yield, allowed amount, contractual adjustment, patient responsibility, days to payment, write-offs, refunds, and recoupments by payer, code, indication, and site. Separate billed charges from allowed amounts and allowed amounts from cash. Add accessioning, reagents, labor, sequencing or instrument time, pathologist review, shipping, recollection, billing, prior authorization, evidence support, and bad debt. Contribution margin per reportable, paid result is more informative than gross margin per accessioned specimen.

The physician investor's seven-part diligence framework

1. Lock the regulatory perimeter to production facts

Create a version-controlled inventory of the assay, instruments, reagents, software, algorithm, collection materials, report, claims, intended users, legal entities, laboratory sites, and distribution. Require a dated regulatory rationale for each component and a review gate for changes. Test planned expansion scenarios: another specimen type, home collection, direct consumer access, a second laboratory, a licensed algorithm, a partner instrument, or a kit sold to customers. Each can alter evidence, quality, state, and FDA assumptions.

2. Trace one result through the complete evidence chain

Select a representative positive, negative, borderline, invalid, and amended result. Trace each from order and specimen through raw data, quality controls, algorithm version, review, report, clinical action, claim, and outcome. Confirm that identifiers link the record to the current method dossier. Ask what happens when the reference range changes, a sample fails, the model returns a low-confidence output, or the result conflicts with pathology or follow-up. A polished report without traceability is a presentation layer, not an evidence system.

3. Audit the laboratory as the production facility

Review the CLIA certificate, specialties, most recent survey, deficiencies, plan of correction, accreditation, laboratory-director oversight, personnel files, competency, quality management, proficiency testing, equipment maintenance, environmental controls, vendor qualification, document control, complaints, corrective and preventive actions, and business continuity. Inspect shift and weekend coverage, not just leadership interviews. Compare validated capacity with peak demand and include maintenance, repeat runs, failures, staffing vacancies, and supply shortages.

4. Reconcile commercial claims with clinical evidence

Compare the website, sales deck, report, clinician education, payer dossier, publications, and customer contract to the intended use and supporting studies. Flag claims that move from association to diagnosis, from risk prediction to treatment selection, or from subgroup exploration to broad population benefit. Ask clinicians how the result changes care and what they do when it disagrees with existing evidence. Physician investors are well positioned to detect a test that is scientifically interesting but operationally unactionable.

5. Prove coverage-to-cash by cohort

Define the reimbursable cohort from active covered indications, payer policies, ordering rules, sites, documentation, prior authorization, and patient access. Reconcile that cohort to invoices and adjudicated claims. Build downside cases for noncoverage, coding changes, narrower indications, lower allowed amounts, contractor variation, recoupments, and slower payment. Consumer cash-pay demand should be modeled separately with refunds, collection failure, support, and acquisition cost rather than used to hide payer friction.

6. Model scale as method transfer plus logistics

A software-like revenue curve can conceal laboratory physics. Model specimen collection density, transport distance, stability, batch size, instrument utilization, labor specialization, reruns, no-calls, storage, bioinformatics, report review, and customer support. If the plan adds laboratories, price method transfer, bridging or validation, personnel, permits, quality harmonization, and inter-site comparability. If it keeps one site, price redundancy, disaster recovery, courier coverage, extended hours, and the working capital created by turnaround and claims lag.

7. Align contracts, financing, and exit assumptions

Customer and vendor contracts should allocate ordering, specimen quality, data rights, result use, regulatory cooperation, quality events, uptime, service levels, recalls or corrections, indemnity, insurance, evidence publication, payment, and termination assistance. Financing should cover laboratory build-out, validation, clinical studies, payer dossiers, state approvals, quality staffing, and delayed collections. For an acquisition case, test whether the buyer can preserve the single-laboratory model or whether integration, assay transfer, branding, and distribution would change the regulatory and economic premise.

Investment committee scorecard

Red flags that should change price or terms

• Management says the court decision deregulated LDTs and cannot produce a component-level regulatory analysis for the current product.
• The assay is described as single-laboratory, but core reagents, algorithms, reports, or production steps are distributed or replicated without a clear rationale.
• The method dossier does not match the current specimen, instrument, cutoff, software version, reference range, or commercial report.
• Clinical claims rely on analytical accuracy, retrospective association, or selected case studies without population-matched clinical validity or utility.
• New York or other regulated states appear in the pipeline, but the approval matrix has missing submissions, owners, dependencies, or realistic dates.
• Coverage slides cite a code or CLFS amount, while the company cannot show an active policy, covered indication, required identifier, or paid claims by jurisdiction.
• Gross margin excludes failed specimens, repeats, shipping, pathologist review, quality staff, billing appeals, evidence generation, and cash lag.
• Multi-site expansion is modeled as copying software rather than transferring and validating a laboratory method under a unified quality system.
• A strategic-buyer valuation assumes the assay can move to the buyer's laboratory without new validation, state, contract, or regulatory consequences.

Frequently asked questions

Did the 2025 court decision eliminate FDA oversight of every laboratory test?

No. The court vacated the 2024 rule that would have phased out FDA's general enforcement-discretion approach for LDTs, and FDA later restored the prior regulatory text. That does not turn every diagnostic business into an LDT or immunize distributed kits, instruments, software, collection products, direct-to-consumer claims, or other regulated components. Investors should map the actual product, manufacturer, laboratory, distribution, claims, and workflow with qualified regulatory counsel.

Is CLIA certification evidence that an LDT is clinically useful?

Not by itself. CLIA establishes laboratory quality requirements and requires performance specifications for the test system, but a company's commercial thesis may also depend on clinical validity and clinical utility in a defined population and care pathway. Investors should examine each layer separately and ask whether using the result changes a clinical decision or outcome that a payer or customer values.

Why does a single-laboratory model matter to LDT valuation?

The classic LDT model is designed, manufactured, and used within one laboratory. Centralization can preserve control and concentrate expertise, but it also concentrates specimen logistics, turnaround time, personnel, capacity, downtime, and geographic risk. Replicating the assay at another laboratory, transferring production, or distributing components can change the regulatory and validation analysis, so scale should be modeled as an operating architecture rather than a simple software rollout.

Does a CLFS payment amount guarantee Medicare coverage for a new test?

No. Coding, coverage, and payment are different gates. A code or fee-schedule amount does not prove that the test is covered for the intended indication, patient, ordering pathway, or contractor jurisdiction. Molecular tests may also face MolDX registration, technical assessment, identifier, documentation, and reasonable-and-necessary requirements before clean claims become repeatable cash.

What is the most important data-room request for an LDT startup?

Request a traceable test dossier linked to the production assay and real claims. It should connect intended use, specimen and preanalytics, analytical validation, clinical evidence, software and algorithm version, reference ranges, quality control, proficiency testing or alternative assessment, report language, ordering rules, coverage decisions, denials, cash, complaints, corrective actions, and every material change. The linkage matters more than the volume of documents.

Conclusion

The FDA rule vacatur changed the federal regulatory baseline, but it did not collapse the diligence stack into one yes-or-no question. A valuable LDT company must still operate a high-complexity laboratory, maintain a production-matched validation dossier, establish clinical relevance, navigate state approvals, secure coverage, collect claims, and scale specimen logistics without losing reproducibility. Physician investors should reward companies that can connect one patient order to one defensible result, one clinical action, one compliant claim, and one measurable margin. They should discount businesses whose growth requires the assay to become something materially different from the model on which its evidence and regulatory assumptions were built.

References

1. U.S. Food and Drug Administration. Laboratory Developed Tests. Current through August 8, 2026. Accessed August 8, 2026. https://www.fda.gov/medical-devices/in-vitro-diagnostics/laboratory-developed-tests
2. U.S. Food and Drug Administration. Medical Devices; Laboratory Developed Tests; Final Rule Reverting Regulatory Text After Vacatur. Federal Register. September 19, 2025. Accessed August 8, 2026. https://www.federalregister.gov/documents/full_text/html/2025/09/19/2025-18239.html
3. Centers for Medicare & Medicaid Services. Clinical Laboratory Improvement Amendments. Updated 2026. Accessed August 8, 2026. https://www.cms.gov/medicare/quality/clinical-laboratory-improvement-amendments
4. Centers for Medicare & Medicaid Services. Laboratory Developed Tests: Frequently Asked Questions. CLIA Overview. Accessed August 8, 2026. https://www.cms.gov/regulations-and-guidance/legislation/clia/downloads/ldt-and-clia_faqs.pdf
5. Centers for Disease Control and Prevention. Test Complexities: Clinical Laboratory Improvement Amendments. September 11, 2024. Accessed August 8, 2026. https://www.cdc.gov/clia/php/test-complexities/index.html
6. Centers for Medicare & Medicaid Services. State Operations Manual, Appendix C: Survey Procedures and Interpretive Guidelines for Laboratories and Laboratory Services, section 493.1253. Accessed August 8, 2026. https://www.cms.gov/files/document/apcsubk1pdf
7. Centers for Medicare & Medicaid Services. CLIA Proficiency Testing Programs. Updated July 2, 2026. Accessed August 8, 2026. https://www.cms.gov/medicare/quality/clinical-laboratory-improvement-amendments/proficiency-testing
8. New York State Department of Health, Wadsworth Center. Clinical Laboratory Evaluation Program. Current through August 8, 2026. Accessed August 8, 2026. https://wadsworth.org/regulatory/clep
9. Centers for Medicare & Medicaid Services. Clinical Laboratory Fee Schedule. Updated July 6, 2026. Accessed August 8, 2026. https://www.cms.gov/medicare/payment/fee-schedules/clinical-laboratory-fee-schedule-clfs
10. Centers for Medicare & Medicaid Services. Local Coverage Determination L35160: MolDX Molecular Diagnostic Tests. Revision effective February 5, 2026. Accessed August 8, 2026. https://www.cms.gov/medicare-coverage-database/view/lcd.aspx?LCDId=35160

Editorial disclaimer: This article is for educational purposes only and does not constitute medical, legal, tax, accounting, regulatory, reimbursement, privacy, laboratory-quality, or investment advice. Laws, court decisions, agency positions, coverage policies, laboratory requirements, and company facts can change. Readers should consult qualified professionals and verify current primary sources before acting. Evidence reviewed through August 8, 2026.